Keyword: Orilissa

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

In light of increased antitrust scrutiny over pharma M&A, AbbVie will also cut a few products to win U.S. clearance for its Allergan buyout.

AbbVie's Humira just posted its first-ever drop in worldwide sales—and with biosimilars on the march in Europe, it's not likely to be the last.

AbbVie’s first campaign for Orilissa is a play on the brand name for the endometriosis pain drug.

AbbVie’s Orilissa snagged its first FDA approval over the summer, and now it’s looking to make it two.

Over the first nine months of 2018, the Illinois pharma has paid just 4.5% of the income taxes it shelled out over the same period last year.

At Orilissa's current price, only a quarter of eligible patients could get the drug without crossing the healthcare burden threshold, ICER estimates.

One of AbbVie’s most anticipated pipeline candidates—and a potential blockbuster aid after Humira biosims hit—has reached the regulatory finish line.